Cold Chain Smart Solutions Conference

Fleming Europe19 - 21 January 2011, Barcelona, Spain
The Cold Chain Smart Solutions Conference is the perfect place to get up to speed with the latest regulations, technology and processes that are necessary to operate a cost-effective and compliant temperature controlled supply chain.

Due to greater temperature ranges and novel biotech drugs coming onto market the number of cold chain shipments by air, road and sea continue increasing. Temperature controlled and pharmaceutical shipping are widely expected to lead the recovery in terms of growth rates. Therefore the most immediate investment priorities of pharmaceutical, shipper, wholesaler companies and CMOs should include cold chain capabilities.

By attending you will have the chance to listen to conference presentations, panel discussions, specialist discussion forums, tailor-made streams about the burning topics of the industry - such as the most updated regulatory roadmap, quality systems and agreements, RF-enabled product visibility, electronic temperature monitoring, satellite tracking, "Last mile" issues, new market focus on Asia, shipping by ocean, cold chain packaging & shipping smart solutions: PCM, going green, active ULDs, battery-assisted passive RFID, etc.

In the frame of a highly interactive Post-Conference Workshop you will gain an insight into the newest real-life strategies how to mitigate the risks and optimize the cold chain costs efficaciously.

Furthermore, you will have excellent opportunities to network with temperature controlled supply chain stakeholders from:

  • Pharmaceutical, Biotech and Medical Device Manufacturers
  • Transportation Providers
  • Government Healthcare Agencies and Shippers
  • Freight forwarders
  • Packaging Partners
  • Wholesalers

As a comprehensive and one-of-its kind event, the Cold Chain Smart Solutions Conference will address the most urgent challenges of the global marketplace for the storage and distribution of temperature sensitive pharmaceuticals, biopharmaceuticals, vaccines, etc.

For further information and brochure request, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/cold-chain-smart-solutions

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...